Biochemical and cellular evidence of the benefit of a combination of cerium oxide nanoparticles and selenium to diabetic rats

Table 4 Effects of various treatments on plasma cholesterol, triglyceride and lipoproteins (mean ± SE)

Animal Groups	Cholestrol (mg/dL)	Triglyceride (mg/dL)	HDL (mg/dL)	LDL (mg/dL)
Control	69.41 ± 7.02	70.66 ± 6.66	41.28 ± 2.27	36.37 ± 1.91
Diabetic control	110.20 ± 5.09b	166.09 ± 8.53c	30.14 ± 1.83b	51.42 ± 2.80b
Cerium oxide	109.98 ± 5.53c	166.05 ± 10.03c,f	29.00 ± 1.95c,f	60.14 ± 1.62c,g
Nanocerium oxide	107.02 ± 1.48b	123.37 ± 8.72b,d	38.42 ± 1.46d	49.00 ± 2.80a
Sodium selenite	102.22 ± 6.77b	123.25 ± 6.43b,d	38.00 ± 1.43d	40.66 ± 2.66d
Nanocerium oxide + Sodium selenite	106.15 ± 5.79b	113.10 ± 8.17a,e	39.60 ± 2.13d	39.14 ± 2.79d

^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs control group; ^dP < 0.01, ^eP < 0.01 vs diabetic control group; ^fP < 0.01, ^gP < 0.001 vs Nanocerium oxide + Sodium selenite group. HDL: High density lipoprotein; LDL: Low density lipoprotein.